TUCSON   520.748.4400

Antitope Ltd. and RCT Announce Protein Deimmunisation Research Agreement

4.22.2013

Alcon and ThromboGenics Announce EU Approval of Pichia-manufactured Jetrea®

3.18.2013

Vimpat® (Lacosamide) Generates Positive Results in U.S. Phase 3 Monotherapy Study

3.5.2013

BioCision Raises $2.5 Million Growth Financing to Support Continued Expansion

12.4.2012

UCB Commences Phase 3 Lacosamide Study in Asia

11.19.2012

Pichia-manufactured Jetrea® Approved by FDA for the Treatment of Symptomatic Vitreomacular Adhesion

10.18.2012

Option 3’s Laproscopic Fascial Closure System Awarded Innovation of the Year

8.28.2012

Esperance Pharmaceuticals Completes Run-in Enrollment of Phase 2 Clinical Trial of EP-100

8.28.2012

RCT demonstrates long half-life of CH2 domains

7.11.2012

RCT partners with Isogenica for large-scale screening of CH2 domains

7.11.2012